American journal of diseases of children (1960) · 1993
The use of primidone in neonates with theophylline-resistant apnea.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miller C A, Gaylord M, Lorch V, Zimmerman A W
Аннотация
OBJECTIVE: To determine whether primidone reduced the occurrence of apnea of prematurity in neonates with apnea resistant to theophylline.
DESIGN: Retrospective review.
SETTING: Neonatal intensive care unit.
PARTICIPANTS: Sixteen premature infants (mean age, 27.8 weeks) in whom apnea and bradycardia recurred despite therapeutic levels of theophylline. Six of the patients were receiving assisted ventilation.
INTERVENTION: Administration of primidone (10 to 15 mg/kg per day) orally or by nasogastric tube at a mean age of 35 days.
RESULTS: Apnea and bradycardia decreased significantly 24 to 72 hours after initiation of primidone treatment (by 68% and 69%, respectively) compared with pretreatment events. We obtained similar results after a separate analysis of the 10 patients who had been weaned from assisted ventilation before treatment with primidone. No toxic reactions were observed.
CONCLUSIONS: Primidone represents a possible adjuvant therapy in theophylline-resistant apnea of prematurity. Caution is advised, because of primidone's complex pharmacologic characteristics, until there are further controlled prospective studies.
DESIGN: Retrospective review.
SETTING: Neonatal intensive care unit.
PARTICIPANTS: Sixteen premature infants (mean age, 27.8 weeks) in whom apnea and bradycardia recurred despite therapeutic levels of theophylline. Six of the patients were receiving assisted ventilation.
INTERVENTION: Administration of primidone (10 to 15 mg/kg per day) orally or by nasogastric tube at a mean age of 35 days.
RESULTS: Apnea and bradycardia decreased significantly 24 to 72 hours after initiation of primidone treatment (by 68% and 69%, respectively) compared with pretreatment events. We obtained similar results after a separate analysis of the 10 patients who had been weaned from assisted ventilation before treatment with primidone. No toxic reactions were observed.
CONCLUSIONS: Primidone represents a possible adjuvant therapy in theophylline-resistant apnea of prematurity. Caution is advised, because of primidone's complex pharmacologic characteristics, until there are further controlled prospective studies.